ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
8 announcements
Jagsonpal Pharmaceuticals Ltd will acquire the Wellness Portfolio of Group Pharmaceuticals Ltd. The transaction involves a total consideration capped at ₹46.7 Crore.
Jagsonpal Pharmaceuticals held its 47th Annual General Meeting on September 18, 2026. Shareholders transacted business including adoption of financial statements and director appointments.
Jagsonpal reported a strong Q1FY27 with 9% revenue growth and 22% PAT growth, outperforming industry rates. The focus is on higher-margin specialty segments and integrating the Equitas acquisition to enter the hospital channel.
Jagsonpal Pharmaceuticals reported a strong start to FY27 with revenue up 9% YoY and PAT up 22%. The company completed the Aequitas acquisition to enter the hospital supplies segment.
Jagsonpal Pharmaceuticals Ltd reported revenue from operations of ₹82.2 Cr (+8.7% YoY) and net profit of ₹13.2 Cr (+22.2% YoY) for Q1 FY27.
Jagsonpal reported Q4 revenue of ₹64cr (up 10% YoY) and FY26 revenue of ₹287cr (up 7%). Strategy focuses on MR productivity and portfolio rejuvenation in Gynaecology and Dermatology.
Jagsonpal Pharmaceuticals reported strong FY26 results with 7% revenue growth and 19% PAT growth. Strategy focuses on an asset-light model, high-margin Rx brands, and shareholder returns via buybacks and dividends.
Jagsonpal Pharmaceuticals Ltd reported revenue from operations of ₹64.2 Cr (+9.6% YoY) and net profit of ₹8.8 Cr (+33.3% YoY) for Q4 FY26.